Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akcea Therapeutics, Inc.    AKCA

AKCEA THERAPEUTICS, INC.

(AKCA)
  Report
SummaryQuotesChartsNewsRatingsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Most relevant news about AKCEA THERAPEUTICS, INC.
11/10IONIS PHARMACEUTICALS : Akcea Therapeutics - WAYLIVRA, the first and only therap..
AQ
11/09IONIS PHARMACEUTICALS : and Akcea Recognize FCS Awareness Day with Global Commun..
AQ
11/04Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study ..
AQ
11/02IONIS PHARMACEUTICALS : and Akcea win prestigious Prix Galien Award for TEGSEDI ..
AQ
10/13IONIS PHARMACEUTICALS : completes acquisition of Akcea Therapeutics
AQ
10/12AKCEA THERAPEUTICS : Ionis Pharmaceuticals completes acquisition of Akcea Therap..
PR
09/18AKCEA THERAPEUTICS : WAYLIVRA▼® (volanesorsen), the First and Only Therapy..
BU
09/11WeissLaw LLP Reminds AKCA and AIMT Shareholders About Its Ongoing Investigati..
PR
09/05KASKELA LAW LLC : Announces Stockholder Investigation of Akcea Therapeutics, Inc..
PR
09/04AKCEA INVESTOR ALERT BY THE FORMER A : Kahn Swick & Foti, LLC Investigates Adequ..
BU
09/01Monteverde & Associates PC Announces an Investigation of Akcea Therapeutics, ..
PR
08/31AKCEA THERAPEUTICS : Ionis Pharmaceuticals to acquire remaining stake in Akcea T..
PR
08/25AKCEA THERAPEUTICS : and Ionis to Present Phase 2 Clinical Data of Vupanorsen at..
AQ
08/14AKCEA THERAPEUTICS : Announces New Pricing and Reimbursement of WAYLIVRA in Germ..
AQ
08/04AKCEA THERAPEUTICS : 2Q Earnings Snapshot
AQ
08/04AKCEA THERAPEUTICS : Reports Financial Results and Highlights for Second Quarter..
PR
07/23AKCEA THERAPEUTICS : Announces Approval for Reimbursement of TEGSEDI in Austria ..
AQ
07/22AKCEA THERAPEUTICS : Announces Approval for Reimbursement of TEGSEDI® (inotersen..
PR
07/21AKCEA THERAPEUTICS : Appoints New Senior Vice President, Global Medical Affairs
AQ
06/29AKCEA THERAPEUTICS : Appoints Tracy Palmer Berns as Chief Compliance Officer
PR
06/09AKCEA THERAPEUTICS : announces approval for reimbursement of TEGSEDI in Italy fo..
AQ
06/08AKCEA THERAPEUTICS : announces approval for reimbursement of TEGSEDI® (inotersen..
PR
06/02AKCEA THERAPEUTICS : announces approval for reimbursement of TEGSEDI in Portugal..
AQ
06/01AKCEA THERAPEUTICS : announces approval for reimbursement of TEGSEDI® (inotersen..
PR
05/29AKCEA THERAPEUTICS : and Ionis Announce Publication of Long-Term Clinical Data o..
AQ
05/28Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® i..
GL
05/15AKCEA THERAPEUTICS : Announces Approval for Reimbursement of TEGSEDI in Spain fo..
AQ
05/14AKCEA THERAPEUTICS : Announces Approval for Reimbursement of TEGSEDI® (inotersen..
PR
05/13AKCEA THERAPEUTICS : Canada Confirms Letter of Intent with Pan-Canadian Pharmace..
AQ
05/05AKCEA THERAPEUTICS : 1Q Earnings Snapshot
AQ
04/21Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
GL
04/10AKCEA THERAPEUTICS INVESTOR ALERT : Investigation on Behalf of Akca Shareholders
NE
04/09AKCEA THERAPEUTICS : Nationally Ranked Shareholder Rights Firm Labaton Sucharow ..
BU
03/24Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
GL
03/13AKCEA THERAPEUTICS : Canada celebrates official launch of first-of-its-kind rese..
AQ
03/12AKCEA THERAPEUTICS : Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior V..
AQ
03/11Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New..
GL
03/04AKCEA THERAPEUTICS : SEC Filing (DEFA14C)
PU
03/04AKCEA THERAPEUTICS : SEC Filing (DEF 14C)
PU
03/02AKCEA THERAPEUTICS : Supports Rare Disease Day 2020 and Global Efforts to 'Refra..
AQ
02/28Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rar..
GL
02/26Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
GL
02/25AKCEA THERAPEUTICS : 4Q Earnings Snapshot
AQ
02/25AKCEA THERAPEUTICS : Reports Financial Results and Highlights for Fourth Quarter..
AQ
02/18Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Result..
GL
02/13Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
GL
01/28Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL..
GL
01/22AKCEA THERAPEUTICS : and Ionis report positive topline Phase 2 results of -APOCI..
PR
01/13AKCEA THERAPEUTICS : and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 ..
AQ
01/10Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Tri..
GL
01/03AKCEA THERAPEUTICS : New England Journal of Medicine Publishes Results from Phas..
AQ
01/02New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA..
GL
2019AKCEA THERAPEUTICS : Retains Rights to -APOCIII-LRx
AQ
2019Akcea Therapeutics Announces New Appointments to its Board of Directors
GL
2019Akcea Announces Appointment of New Chief Operating Officer
GL
2019Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Tria..
GL
2019Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for ..
GL
2019Akcea Therapeutics to Present at Upcoming Investor Conferences
GL
2019Akcea Reports Financial Results and Highlights for Third Quarter 2019
GL
2019Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Co..
GL
2019Akcea Announces Appointment of New Chief Commercial Officer
GL
2019Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
GL
2019Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisens..
GL
2019Akcea Announces CEO Transition and Elects Two New Board Members
GL
2019Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Soci..
GL
2019Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upco..
GL
2019Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA®..
GL
2019Akcea Reports Financial Results and Highlights for Second Quarter 2019
GL
2019Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast
GL
2019hATTR Compass™ Genetic Testing Program Continues to Expand and Enable D..
GL
2019Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Acad..
GL
2019Akcea Reports Financial Results and Highlights for First Quarter 2019
GL
2019Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European..
GL
2019Akcea Announces Upcoming Data Presentations at the 2019 American Academy of N..
GL
2019Akcea Therapeutics to Hold First Quarter 2019 Financial Results Webcast
GL
1  2Next